N-ethyl-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-N-(2-methoxyethyl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-ethyl-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-N-(2-methoxyethyl)benzamide
• 化学式: C₁₅H₁₇F₆NO₃
• 分子量: 373.29
• InChiKey: RFJFFGFAFROHDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
  申请人：——

  公开号：US20040087627A1

  公开（公告）日：2004-05-06

  The present invention relates to methods for the prophylaxis, management and treatment of certain diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD) by the administration of a composition containing as an active ingredient a compound according to Formula I. In particular, the invention relates to methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the administration of a compound which inhibits malonyl-coenzyme A decarboxylase activity. The present invention also includes within its scope the novel process for the preparation of certain compounds. 1

  本发明涉及通过给予含有化合物I的活性成分的组合物来抑制麦芽酰辅酶A脱羧酶（malonyl-CoA脱羧酶，MCD）的方法，用于预防、管理和治疗某些由该酶抑制调节的疾病。特别地，本发明涉及通过给予抑制麦芽酰辅酶A脱羧酶活性的化合物来预防、管理和治疗心血管疾病、糖尿病、酸中毒、癌症和肥胖症的方法。本发明还包括其范围内的新型化合物制备方法。1
• METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1353662A2

  公开（公告）日：2003-10-22
• JP2004521113A
  申请人：——

  公开号：JP2004521113A

  公开（公告）日：2004-07-15
• マロニル−ＣｏＡ脱炭酸酵素阻害剤を用いた疾患の治療法
  申请人：中外製薬株式会社

  公开号：JP4503232B2

  公开（公告）日：2004-07-15
• [EN] METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS<br/>[FR] PROCEDES RELATIFS AU TRAITEMENT DE MALADIES PAR LE BIAIS D'INHIBITEURS DE MALONYL-COA DECARBOXYLASE
  申请人：CHUGAI PHARMACEUTICAL CO LTD

  公开号：WO2002058690A2

  公开（公告）日：2002-08-01

  The present invention relates to methods for the prophylaxis, management and treatment of certain diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD) by the administration of a composition containing as an active ingredient a compound according to Formula I. In particular, the invention relates to methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the administration of a compound which inhibits malonyl-coenzyme A decarboxylase activity. The present invention also includes within its scope the novel process for the preparation of certain compounds.